Category: Takeda

Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated) Video

0 views | February 1, 2023 Oncotarget published this research paper in Volume 14, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)” by the researchers from the Division of Hematology and Oncology, Northwestern University Feinberg School of…

Continue Reading Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated) Video

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

“The current analysis provides updated results for these lymphoma patients with extended follow-up.”  Listen to an audio version of this press release BUFFALO, NY- February 1, 2023 – A new research paper was published in Oncotarget’s Volume 14 on January 26, 2023, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in…

Continue Reading Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut

Finch Therapeutics’ lead microbiome therapy reached Phase 3 testing as a potential treatment for a serious and potentially fatal gut infection, but study enrollment challenges and financial headwinds have led the biotech to end the program and instead find ways to monetize its remaining assets. The corporate restructuring will lead…

Continue Reading Gut Punch: Finch’s Flagging Microbiome Program Folds, Leading to 95% Staff Cut

Finch stops phase 3, lays off 95% of staff and plans asset sale

Finch Therapeutics is throwing in the towel. Shortly after getting its phase 3 clinical trial back on track, the microbiome biotech has decided to stop the study and seek to offload assets in the face of a frosty funding forecast and slow enrollment. The Massachusetts-based biotech has endured a tough…

Continue Reading Finch stops phase 3, lays off 95% of staff and plans asset sale

AstraZeneca eagerness for CinCor revealed in larger first offer

AstraZeneca kicked off this year’s J.P.Morgan Healthcare Conference in style, announcing a $1.8 billion deal that gave it ownership of CinCor Pharma and its mid-phase hypertension drug baxdrostat. But while Fierce Biotech reported at the time that AstraZeneca was able to exploit CinCor’s deflated share price, that was only part…

Continue Reading AstraZeneca eagerness for CinCor revealed in larger first offer

Identification of genetic variants associated with diabetic kidney disease in multiple Korean cohorts via a genome-wide association study mega-analysis | BMC Medicine

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–83. Article  Google Scholar  Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension…

Continue Reading Identification of genetic variants associated with diabetic kidney disease in multiple Korean cohorts via a genome-wide association study mega-analysis | BMC Medicine

Ensoma Raises $85M in Series B

Ensoma, a Boston, MA-based genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, raised $85M in Series B funding, and acquired Twelve Bio, a Copenhagen, Denmark-based CRISPR engineering company. The round was co-led by Arix Bioscience and 5AM Ventures with participation from F-Prime Capital,…

Continue Reading Ensoma Raises $85M in Series B

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off…

Continue Reading MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Medical Advance Conquers Stock Market Code List

Thanks to a breakthrough in biotechnology made by two Nobel Prize-winning researchers in 2020, it will soon be possible to treat genetic diseases and cancer through selective gene sharing. The innovative method CRISPR/Cas9 it has also aroused interest among investors, thanks to which both Nobel laureates were able to create…

Continue Reading Medical Advance Conquers Stock Market Code List

The Accept Phase Ib/II Single Arm Study

Oral and Poster Abstracts 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Research, clinical trials, Lymphomas, Clinical Research, Combination therapy, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Andrew J Davies, BSc, BM, FRCP, PhD1,2*, Josh Caddy, BSc3*, Katy McLaughlin, BSc3*, Christopher Wignall, MSc3*, Robert…

Continue Reading The Accept Phase Ib/II Single Arm Study

Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

Visiongain Reports Ltd Global Gene Therapy R&D Market Forecast 2021-2031: – Market Segment by Disease {Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases}, Vector {Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)}, Techniques (Gene Augmentation Therapy, Gene Replacement…

Continue Reading Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

Bioinformatics Analysis of the Key Genes and Pathways in Multiple Myel

Introduction Multiple myeloma is a B-cell malignancy characterized by the malignant proliferation of clonal plasma cells in bone marrow,1 It is the second most common hematological malignancy after lymphoma.2 The age-standardised rate (ASR) of multiple myeloma incidence was 1·78 (95% UI 1·69-1·87) per 100 000 people globally and mortality was…

Continue Reading Bioinformatics Analysis of the Key Genes and Pathways in Multiple Myel

Convenience-sized RNA editing | MIT News

Last year, researchers at MIT’s McGovern Institute for Brain Research discovered and characterized Cas7-11, the first CRISPR enzyme capable of making precise, guided cuts to strands of RNA without harming cells in the process. Now, working with collaborators at the University of Tokyo, the same team has revealed that Cas7-11…

Continue Reading Convenience-sized RNA editing | MIT News

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

ISPE announces 2022 Facility of the Year Awards winners

Winners of ISPE’s Facility of the Year Awards (FOYA) 2022 include Janssen, Takeda, CRISPR Therapeutics, Catalent and Iovance Biotherapeutics. ISPE has announced the 2022 Facility of the Year Awards (FOYA) Category Winners at the 2022 ISPE Europe Annual Conference in Madrid, Spain.  FOYA is the global awards programme recognising innovation and creativity…

Continue Reading ISPE announces 2022 Facility of the Year Awards winners

Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer

Significance During the aging process, senescent cells secrete inflammatory factors, causing various age-related pathologies. Thus, controlling the senescence-associated secretory phenotype (SASP) can tremendously benefit human health. Although SASP seems to be induced by the alteration of chromosomal organization, its underlying mechanism remains unclear. Here, it has been revealed that noncoding…

Continue Reading Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer